MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kedzie, K. M.
Right arrow Articles by Gil, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kedzie, K. M.
Right arrow Articles by Gil, D. W.

Vol. 54, Issue 3, 584-590, September 1998

A Single Amino-Acid Substitution in the EP2 Prostaglandin Receptor Confers Responsiveness to Prostacyclin Analogs

Karen M. Kedzie, John E. Donello, Heather A. Krauss, John W. Regan, and Daniel W. Gil

Department of Biological Sciences, Allergan, Inc., Irvine, California 92623-9534 (K.M.K., J.E.D., H.A.K., D.W.G.) and the Department of Pharmacology & Toxicology, Department of Physiology, and the Program in Neuroscience, University of Arizona, Tucson, Arizona 85721 (J.W.R.)

A high degree of homology between the four Gs-coupled prostaglandin (PG) receptors [EP2, EP4, prostacyclin (IP), PGD2 (DP)] and the four Gq/Gi-coupled receptors [EP1, EP3, PGF2alpha (FP), thromboxane A2 (TP)] suggests that prostaglandin receptors evolved functionally from an ancestral EP receptor before the development of distinct binding epitopes. If so, ligand selectivity should be determined by a limited number of amino acids. EP2 receptor transmembrane domain residues that are similar to those in the EP4 receptor but differ from those in the IP receptor were mutated to the corresponding IP receptor residue. Activation of the mutant receptors by PGE2 (EP2 ligand), iloprost (stable prostacyclin analog), and PGE1 (EP2/IP ligand) was determined using a cAMP-dependent reporter gene assay. A Leu304-to-tyrosine substitution in the seventh transmembrane domain enhanced iloprost potency approximately 100-fold. A glycine substitution at Ser120 in the third transmembrane domain had no effect on drug potency but improved the response of the Tyr304 mutant. The potency of the natural prostaglandins PGF2alpha and PGD2 was not enhanced by the mutations. In contrast, the potency of all prostaglandins was reduced 10- to 100-fold when arginine 302, which is thought to be a counterion for the prostaglandin carboxylic acid, was mutated. Thus, a single amino acid change resulted in a selective gain of function for iloprost, which is consistent with the proposed phylogeny of the prostaglandin receptors.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Circ. Res.Home page
R. Li, K. P. Mouillesseaux, D. Montoya, D. Cruz, N. Gharavi, M. Dun, L. Koroniak, and J. A. Berliner
Identification of Prostaglandin E2 Receptor Subtype 2 As a Receptor Activated by OxPAPC
Circ. Res., March 17, 2006; 98(5): 642 - 650.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Stitham, A. Stojanovic, B. L. Merenick, K. A. O'Hara, and J. Hwa
The Unique Ligand-binding Pocket for the Human Prostacyclin Receptor. SITE-DIRECTED MUTAGENESIS AND MOLECULAR MODELING
J. Biol. Chem., January 31, 2003; 278(6): 4250 - 4257.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
F. Stoll, S. Liesener, T. Hohlfeld, K. Schror, P. L. Fuchs, and H.-D. Holtje
Pharmacophore Definition and Three-Dimensional Quantitative Structure-Activity Relationship Study on Structurally Diverse Prostacyclin Receptor Agonists
Mol. Pharmacol., November 1, 2002; 62(5): 1103 - 1111.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Hatae, M. Wada, C. Yokoyama, M. Shimonishi, and T. Tanabe
Prostacyclin-dependent Apoptosis Mediated by PPARdelta
J. Biol. Chem., November 30, 2001; 276(49): 46260 - 46267.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. D. Breyer and R. M. Breyer
Prostaglandin E receptors and the kidney
Am J Physiol Renal Physiol, July 1, 2000; 279(1): F12 - F23.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
S. Narumiya, Y. Sugimoto, and F. Ushikubi
Prostanoid Receptors: Structures, Properties, and Functions
Physiol Rev, October 1, 1999; 79(4): 1193 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
B. A. Stillman, M. D. Breyer, and R. M. Breyer
Importance of the Extracellular Domain for Prostaglandin EP2 Receptor Function
Mol. Pharmacol., September 1, 1999; 56(3): 545 - 551.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
T. Kobayashi, F. Ushikubi, and S. Narumiya
Amino Acid Residues Conferring Ligand Binding Properties of Prostaglandin I and Prostaglandin D Receptors. IDENTIFICATION BY SITE-DIRECTED MUTAGENESIS
J. Biol. Chem., August 4, 2000; 275(32): 24294 - 24303.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics